切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2020, Vol. 13 ›› Issue (04) : 470 -474. doi: 10.3877/cma.j.issn.1674-6902.2020.04.008

论著

阿法替尼和顺铂分别联合培美曲塞治疗晚期非小细胞肺癌的疗效分析
郑云威1,(), 黄国定2, 卢宏全2   
  1. 1. 571799 儋州,海南省儋州市中医医院肺病科
    2. 571700 海口,海南西部医院肿瘤内科
  • 收稿日期:2020-04-08 出版日期:2020-08-25
  • 通信作者: 郑云威
  • 基金资助:
    海南省2015年社会发展科技专项基金(SQ2015SHFZ01741)

Clinical efficacies of Afatinib and cisplatin combined with pemetrexed in treatment of advanced non-small cell lung cancer

Yunwei Zheng1,(), Guoding Huang2, Hongquan Lu2   

  1. 1. Department of Pulmonology, Danzhou Traditional Chinese Medicine Hospital, Danzhou 571799, Hainan Province, China
    2. Department of Oncology, Hainan West Hospital, Haikou 571700, Hainan Province, China
  • Received:2020-04-08 Published:2020-08-25
  • Corresponding author: Yunwei Zheng
引用本文:

郑云威, 黄国定, 卢宏全. 阿法替尼和顺铂分别联合培美曲塞治疗晚期非小细胞肺癌的疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2020, 13(04): 470-474.

Yunwei Zheng, Guoding Huang, Hongquan Lu. Clinical efficacies of Afatinib and cisplatin combined with pemetrexed in treatment of advanced non-small cell lung cancer[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(04): 470-474.

目的

探究阿法替尼和顺铂分别联合培美曲塞治疗晚期EFGR突变型非小细胞肺癌晚期(non-small-cell carcinoma, NSCLC)的临床疗效差异,明确阿法替尼临床疗效。

方法

选取我院2016年3月至2017年9月收治的107例EFGR突变阳性晚期NSCLC患者的病例资料,接受顺铂+培美曲治疗的NSCLC患者51例为对照组,接受塞阿法替尼+培美曲塞治疗的NSCLC患者56例,为研究组,观察两组患者疗效、无进展生存时间(progression-free survival time, PFS)以及生存时间(overall survival, OS)等。

结果

研究组患者ORR及DCR比例均明显高于对照组[53.57% vs. 31.37%,85.71% vs. 66.67%,P<0.05];研究组患者PFS及OS均明显高于对照组[7.2月vs. 6.0月,11.75月vs. 9.5月,P<0.05];治疗后,研究组患者神经元特异性烯醇化酶(neuron-specific enolase, NSE)、癌胚抗原(carcinoembryonic antigen, CEA)、细胞角蛋白19片段(cytokeratin 19 fragment, CYFRA21-1)均低于对照组[(11.79±8.51)ng/ml vs.(15.26±8.22)ng/ml,(14.54±8.77)ng/ml vs.(18.37±9.35)ng/ml,(3.45±2.68)ng/ml vs.(5.41±3.54)ng/ml,P<0.05];Ⅰ~Ⅱ级不良反应中,研究组恶心呕吐、肾功能损害及脱发人数比例均明显低于对照组[12.50% vs. 33.33%,5.36% vs. 27.45%,16.07% vs. 35.29%,P<0.05],研究组皮疹/痤疮人数比例明显高于对照组[25.00% vs. 7.84%,P<0.05];治疗后,躯体方面、心理方面、社会方面及总体感觉评分均高于对照组[(77.41±5.25)分vs.(72.12±5.08)分,(74.37±5.40)分vs.(67.52±5.32)分,(79.25±5.98)分vs.(74.32±5.71)分,(71.21±5.45)分vs.(66.61±5.20)分,P<0.05]。

结论

阿法替尼联合培美曲塞一线治疗EGFR突变型晚期NSCLC患者的疗效更为显著,明显提高无进展生存时间及生存时间,明显提高生活质量,同时具有较高安全性,值得临床推广应用。

Objective

To investigate the difference of clinical efficacies of Afatinib and cisplatin combined with pemetrexed respectively in the treatment of the patients with advanced EFGR mutant non-small cell lung cancer (NSCLC) so as to determine the clinical efficacy of Afatinib.

Methods

A total of 107 patients with advanced EFGR mutant NSCLC treated in our hospital from March 2016 to September 2017 were selected for this study. Fifty-one patients treated with cisplatin+ pemetrexed were taken as the control group, while fifty-six patients treated with Afatinib+ pemetrexed were taken as the experimental group. The clinical efficacies, the progression-free survival time (PFST), and the overall survival (OS) were observed for all the patients.

Results

The proportions of ORR and DCR in the experimental group were significantly higher than those of the control group (53.57% vs. 31.37% and 85.71% vs. 66.67%, respectively, P<0.05). The PFST and OS were significantly higher in the experimental group than the control group (7.2 months vs. 6.0 months and 11.75 months vs. 9.5 months, respectively, P<0.05). After treatment, the neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1) of the experimental group were lower than those of the control group [(11.79±8.51) ng/ml vs. (15.26±8.22) ng/ml, (14.54±8.77) ng/ml vs. (18.37±9.35) ng/ml, and (3.45±2.68) ng/ml vs. (5.41±3.54) ng/ml, respectively, P<0.05]. The incidences of nausea and vomiting, renal impairment and hair loss in the experimental group were significantly lower than those of the control group (12.50% vs. 33.33%, 5.36% vs. 27.45%, and 16.07% vs. 35.29%, respectively, P<0.05). The incidence of rash/acne in the experimental group was significantly higher than that of the control group (25.00% vs. 7.84%, P<0.05). After treatment, the physical, psychological, social and overall sensory scores were higher in the experimental group than the control group [(77.41±5.25) scores vs. (72.12±5.08) scores, (74.37±5.40) scores vs. (67.52±5.32) scores, (79.25±5.98) scores vs. (74.32±5.71) scores, and (71.21±5.45) scores vs. (66.61±5.20) scores, respectively, P<0.05].

Conclusion

Afatinib combined with pemetrexed is more effective in the first-line treatment of advanced EGFR mutant NSCLC patients, significantly improves the PFST, the OS and the quality of life of the patients, and has a higher safety, which is worthy of clinical promotion and application.

表1 两组疗效比较[n(%)]
图1 无进展生存时间分析。随着时间增长,研究组患者无进展生存时间会明显长于对照组
图2 生存时间分析。随着时间增长,研究组患者生存时间会明显长于对照组
表2 NSCLC患者肿瘤标志物变化(ng/ml)
表3 NSCLC患者不良反应情况比较[n(%)]
表4 NSCLC患者生活质量评分
1
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet, 2017, 389(10066): 299-311.
2
Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances[J]. Translat Lung Cancer Res, 2016, 5(3): 288.
3
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
4
刘 洋,周 莹,阳 韬,等. 血清结合珠蛋白在非小细胞肺癌诊治中的意义[J]. 江苏大学学报(医学版), 2017, 27(6): 530-532.
5
Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer[J]. Cancer Treatment Reviews, 2016, 44: 42-50.
6
王玉娟,王 莉,康 睿. 培美曲塞与吉西他滨分别联合顺铂治疗晚期非鳞非小细胞肺癌效果及对基质金属蛋白酶及其抑制剂水平影响研究[J]. 临床和实验医学杂志,2017, 16(12): 1193-1195.
7
Qin X, Yu S, Zhou L, et al. Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner[J]. Int J Nanomed, 2017, 12: 3721.
8
Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation[J]. J Thorac Oncol, 2015, 10(6): 910-923.
9
Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial[J]. Lancet Respirat Med, 2018, 6(11): 863-873.
10
Sharma N, Graziano S. Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer[J]. Cancer Treat Rev, 2018, 69: 143-151.
11
Park K, Yu CJ, Kim SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study[J]. JAMA Oncol, 2016, 2(3): 305-312.
12
罗 健,孙 燕,周生余. 中国癌症患者化学生物治疗生活质量量表的编制[J]. 中华肿瘤杂志,1997,17(6): 437-441.
13
罗华婷,刘 锐,陈 川,等. 阿法替尼治疗EGFR突变型晚期非小细胞肺癌的有效性及安全性的研究[J]. 肿瘤药学,2015, 12(6): 466-471.
14
李 倩,李 宵,李 颖,等. 阿法替尼治疗晚期非小细胞肺癌有效性和安全性的系统评价[J]. 中国循证医学杂志,2017, 9(8): 66-71.
15
潘 燚,谭佩欣. 一线阿法替尼与化疗对EGFR突变伴有脑转移的非小细胞肺癌患者的疗效评价[J]. 循证医学,2016, 16(4): 230-232.
16
杨小菊,欧 娜,赵 盼,等. 阿法替尼治疗肺癌的临床研究进展[J]. 药学进展,2017, 41(4): 297-304.
17
龚 磊. 阿法替尼在非小细胞肺癌中的临床应用进展[J]. 中国肿瘤,2018, 27(11): 857-861.
18
施 霞. 阿法替尼和吉非替尼一线治疗EGFR突变阳性非小细胞肺癌的成本效用分析[J]. 中国现代应用药学,2019, 36(21): 2701-2706.
19
薛英杰,贾 靖,吴 杨,等. 培美曲塞和吉西他滨联合阿法替尼治疗晚期非小细胞肺癌临床效果及安全性分析[J]. 临床误诊误治,2020, 33(2): 57-60.
20
刘 涛,闫平钊,杨小花,等. 阿法替尼在老年非小细胞肺癌患者中的应用[J]. 中国老年学杂志,2019, 39(16): 3931-3933.
21
肖 敬,程晓云,张淑平,等. 固摄扶正抗癌汤联合阿法替尼、培美曲塞治疗非小细胞肺癌的临床效果观察[J]. 解放军医药杂志,2019, 31(11): 20-23.
22
王萌萌,苏颖杰,严颐丹. 临床药师对1例贝伐珠单抗联合阿法替尼治疗宫颈癌复发转移患者的药学监护[J]. 中国临床药学杂志,2019, 28(6): 465-467.
23
贵永贤. 重组人血管内皮生成抑制素联合阿法替尼治疗EGFR突变阳性晚期肺腺癌患者的临床效果[J]. 临床医学研究与实践,2020, 5(5): 29-30.
24
谭鑫宇,张 欢,张 杰,等. 阿法替尼治疗非小细胞肺癌患者致严重的药品不良反应影响因素的Logistic回归分析[J]. 中国医院用药评价与分析,2019, 19(9): 1131-1133.
25
马晓东,胡孟奇,陶强强. 马来酸阿法替尼原料药降解杂质的制备与结构推测[J]. 化学世界,2019, 60(3): 177-181.
26
赵仔君,谷晓媛,张为强,等. 贝伐珠单抗联合阿法替尼治疗非小细胞肺癌临床疗效观察[J]. 海南医学院学报,2019, 25(2): 129-132.
27
龚 磊,卢红阳. 阿法替尼在非小细胞肺癌中的临床应用进展[J]. 中国肿瘤,2018, 27(11): 857-861.
28
薛英杰,贾 靖,吴 杨,等. 阿法替尼分别联合培美曲塞、吉西他滨治疗非小细胞肺癌的临床研究[J]. 空军医学杂志,2019, 35(1): 28-31.
[1] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[2] 莫淇舟, 苏劲, 黄健, 李健维, 李思宁, 柳建军. 智能控压输尿管软镜碎石吸引取石术在直径10~25 mm上尿路结石中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 497-502.
[3] 李义亮, 苏拉依曼·牙库甫, 麦麦提艾力·麦麦提明, 克力木·阿不都热依木. 机器人与腹腔镜食管裂孔疝修补术联合Nissen 胃底折叠术短期疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 512-517.
[4] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[5] 王小琴, 汪丽, 崔建英. 无张力疝修补术治疗慢性肾功能衰竭合并腹股沟疝患者的疗效[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 538-542.
[6] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[7] 赖淼, 景鑫, 李桂珍, 李怡. 非小细胞肺癌EGFR 突变亚型的临床病理和预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 731-737.
[8] 王亚岚, 倪婧, 余世庆, 陶银花, 张荣. 尼达尼布抗纤维化治疗特发性肺纤维化的耐受性和疗效预测因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 750-755.
[9] 梁丽斯, 李洁, 贺帅, 来艳君, 刘铭, 张琳. MMP-9、MMP-2 及TLR4、HE4对非小细胞肺癌早期诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 756-761.
[10] 张礼江, 沈玲佳, 施我大. 倾向性评分匹配分析奥希替尼对晚期NSCLC 预后的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 820-822.
[11] 詹济玮, 蔡柳春, 温琼娜, 郭石生, 温春妹, 温鹤明. 布地格福联合噻托溴铵治疗AECOPD 的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 823-826.
[12] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[13] 史彬, 司远. 益气和络方联合缬沙坦治疗气阴两虚兼血瘀证IgA 肾病的疗效观察[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 306-312.
[14] 韩俊岭, 王刚, 马厉英, 连颖, 徐慧. 维生素D 联合匹维溴铵治疗腹泻型肠易激综合征患者疗效及对肠道屏障功能指标的影响研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 560-564.
[15] 阳跃, 庹晓晔, 崔子豪, 欧阳四民, 林海阳, 胡景宇, 胡银, 李涛, 赵景峰, 郝岱峰, 冯光. 改良“阅读者”皮瓣修复骶尾部压疮的疗效[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 751-755.
阅读次数
全文


摘要